ライフサイエンスコーパス: drug safety

1 tential in lead discovery, repositioning and drug safety.

2 e pharmaceutical industry in order to uphold drug safety.

3 d to ensure therapeutic efficacy and enhance drug safety.

4 aceutical strategy to limit DILI and improve drug safety.

5 drug formulation is one approach to improve drug safety.

6 heumatoid arthritis, gout, osteoporosis, and drug safety.

7 ts of CVD, perhaps because of concerns about drug safety.

8 ession, extrapyramidal symptoms, and overall drug safety.

9 tient genetic information to aid in assuring drug safety, a substantial effort is needed in both the

10 ture studies should examine other regulatory drug safety actions, such as the Risk Evaluation and Mit

11 Tertiary end points were drug safety and compliance.

12 Societal expectations about drug safety and efficacy are rising while productivity i

13 within, or attached to, a polymer or lipid, drug safety and efficacy can be greatly improved and new

14 Because data about drug safety and efficacy in adults can rarely be extrapo

15 tool to pin down the relevant biomarker for drug safety and efficacy research.

16 ; mechanistic models of human processes; and drug safety and efficacy studies.

17 ation genetic structure in the evaluation of drug safety and efficacy, and how to relate this structu

18 of multifunctional NPs can lead to improved drug safety and efficacy, and may be complimentary to dr

19 tro to predict and validate patient-specific drug safety and efficacy, potentially enabling future cl

20 cations ranging from accelerating studies of drug safety and efficacy, to identifying pharmacological

21 Ms) provide new possibilities for evaluating drug safety and efficacy.

22 ring, and clinical studies investigating the drug safety and pharmacokinetics are ongoing.

23 f these transporters, which is important for drug safety and physiological studies, we developed a se

24 Further education on drug safety and research into the underlying biological

25 e of the black-box warning system to promote drug safety and to examine the droperidol black-box warn

26 Drug safety and tolerability and Plasmodium falciparum r

27 dverse effects in experimental drugs, and in drug safety, applicable to the evaluation of ADE signals

28 entification (MetID) procedure, essential in drug safety applications and in translational studies.

29 ve ways to communicate new information about drug safety are needed.

30 Current drug-safety assays for hepatotoxicity rely on biomarkers

31 sfy these needs through the development of a drug safety assurance information system (GeneScription)

32 ygenase-2 (COX-2) selectivity and to enhance drug safety by covalent attachment of an organic nitrate

33 er countries with active regulatory systems, drug safety can be adequately ensured, and brand-name pr

34 Despite concerns about drug safety, current information on older adults' use of

35 The drug safety database analysis of mefloquine exposure in

36 Hoffmann-La Roche global drug safety database for the time frame 31 January 1986

37 etwork from a 2009 snapshot of a widely-used drug safety database, and used it to develop PPIN models

38 Using the rituximab global drug safety database, we identified 231 pregnancies asso

39 se was defined as composite understanding of drug safety, dose finding, and dose escalation.

40 y available for these novel agents regarding drug safety, effects on major cardiovascular risk factor

41 Duration of drug safety evaluation was 1 year or less for 26 of 34 t

42 (which most publications are focused on) for drug safety evaluation.

43 eries, suggesting limited validity to assess drug safety for pregnancy outcomes associated with prema

44 Physicians explained drug safety in 23% of ICCs, dose finding in 52% of ICCs,

45 Thus, this sensor can be used to evaluate drug safety in a regime that the current cytotoxicity as

46 paper, the first in a Series of three about drug safety in oncology, we discuss evolving challenges

47 s Series paper, the third of three papers on drug safety in oncology, we review the safety and effica

48 In view of heightening attention on drug safety in patient treatment, lipid-based nanocarrie

49 ns are an important method for disseminating drug safety information, but their impact varies.

50 Although improving drug safety is our goal and obligation to the public, FD

51 e treatments, the need for wiser handling of drug safety issues, the credibility (or lack thereof) of

52 ate abstraction levels to complement current drug safety methods.

53 tial to improve the regulatory assessment of drug safety models under the CiPA paradigm.

54 vents from the biomedical literature assists drug safety monitoring efforts.

55 orized products on the market makes ensuring drug safety more difficult.

56 gned and received at least one dose of study drug; safety outcomes were assessed in all patients who

57 ere driven by concerns over side effects and drug safety, patient preference, drug availability, and

58 ble literature regarding obesity's effect on drug safety, pharmacokinetics, and dosing in obese child

59 tive and automated screening tools to assist drug safety professionals in identifying drug-event comb

60 fy potential DDIs years in advance, enabling drug safety professionals to better prioritize their lim

61 ans use individual patient comorbidities and drug safety profiles.

62 ccess among women included poor knowledge of drug safety, prohibitive costs, and self-treatment pract

63 e number of patients was too small to assess drug safety reliably.

64 ources can be used to augment post-marketing drug safety signal detection.

65 We have developed an efficient and effective drug safety signal ranking and strengthening approach We

66 ein, has a high probability of detecting new drug safety signals.

67 sight is less intensive, and concerns around drug safety still exist.

68 Using 2 example drug safety studies evaluated in 3 cohorts from Pennsylv

69 blishing a viable national program of active drug safety surveillance by using observational data.

70 pe and strengthening the capabilities of the drug safety surveillance system are among key FDA projec

71 ide a resource for diagnosis of DITP and for drug safety surveillance, we analyzed 3 distinct methods

72 l literature can significantly contribute to drug safety surveillance.

73 , a Food and Drug Administration-established drug safety test.

74 Drug safety tests might have to include screening for IK

75 by the Canadian Pharmacogenomics Network for Drug Safety using patients recruited from 5 adult oncolo

76 No major difference in drug safety was observed.

77 oups who received at least one dose of study drug; safety was assessed in all patients who received a

78 tance, and laboratory chemistries reflecting drug safety were recorded.